




Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/773,761
Sheet	1	of	1	Filing Date	February 6, 2004
				First Named Inventor	Erlander, Mark G.
				Art Unit	1634 1636
				Examiner Name	Unassigned Schlapkohl
				Attorney Docket Number	022041-001420US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/WS/	BC	Clarke, R. et al. "Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling", <i>Oncogene</i> 22 (2003) 22:7316-39	
	BD	Jordan, C. "Historical perspective on hormonal therapy of advanced breast cancer", <i>Clin. Ther.</i> (2002) 24 Suppl. A: A3-16	
	BE	Osborne, C.K., et al. "Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer", <i>The Breast</i> (2003) 12:362-7	
	BF	Ellis, M.J. et al. "Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ERB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.", <i>J. Clin Oncol</i> (2001) 19(18):3808-16	
	BG	Buzdar, A.U., "Anastrozole: a new addition to the armamentarium against advanced breast cancer.", <i>Am. J. Clin Oncol</i> (1998) 21(2), 161-6	
	BH	Fabian, et al., "Short-Term Breast Cancer Prediction by Random Periareolar Fine-Needle Aspiration Cytology and the Gail Risk Model", <i>J. Natl Cancer Inst.</i> (2000) 92(15):1217-27	
	BI	Tan-Chiu et al., "Effects of Tamoxifen on Benign Breast Disease in Women at High Risk for Breast Cancer", <i>J. Natl Cancer Inst.</i> (2003) 95(4):302-307	
	BJ	Wickerham, D.L., "Tamoxifen, - an update on current data and where it can now be used", <i>Breast Cancer Res. and Treatment</i> , (2000) 75 Suppl 1:S7-12, Discussion S33-5	
	BK	Fitzgibbons, P.L. et al. "Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999", <i>Arch Pathol Lab Med</i> (2000) 124:966-78	
▼	BL	Ma, X.J. et al., "Gene expression profiles of human breast cancer progression", <i>Proc Natl Acad Sci USA</i> (2003) 100(10):5974-9	
/WS/	BM	Nicholson, R.I. et al., "Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy", <i>Breast Cancer Res Treat</i> (1994) 29:117-25	

Examiner Signature	/Walter Schlapkohl/	Date Considered	6 / 4 / 2007
--------------------	---------------------	-----------------	--------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete If Known	
				Application Number	10/773,761
				Filing Date	February 6, 2004
				First Named Inventor	Erlander, Mark G.
				Art Unit	1634 1636
				Examiner Name	Schlakohl
				Attorney Docket Number	022041-001420US
Sheet	1	of	2		

U.S. PATENT DOCUMENTS+						
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	AA	US-				
	AB	US-				
	AC	US-				
	AD	US-				
	AE	US-				
	AF	US-				
	AG	US-				
	AH	US-				
	AI	US-				
	AJ	US-				
	AK	US-				
	AL	US-				
	AM	US-				
	AN	US-				
	AO	US-				
	AP	US-				
	AQ	US-				
	AR	US-				
	AS	US-				
	AT	US-				

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
/WS/	AU	PCT	WO02/103320	As	12/27/2002	Dai, et al.		<input type="checkbox"/>
	AV							<input type="checkbox"/>
	AW							<input type="checkbox"/>
	AX							<input type="checkbox"/>
	AY							<input type="checkbox"/>
	AZ							<input type="checkbox"/>
	BA							<input type="checkbox"/>
	BB							<input type="checkbox"/>

Examiner Signature		Date Considered
--------------------	--	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ² Applicant's unique citation designation number (optional). ³ Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

60508556v1

JUN 08 2005

PTO/SB/08B (08-03)




Information Disclosure Statement by Applicant <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/773,761
				Filing Date	February 6, 2004
				First Named Inventor	Erlander, Mark G.
				Art Unit	1634 1636
				Examiner Name	Schlakohl
				Attorney Docket Number	022041-001420US
Sheet	2	of	2		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
/WS/	BC	DAIDONE, M.G., et al. "Biomarkers and outcome after tamoxifen treatment in node-positive breast cancers from elderly women", <i>British Journal of Cancer</i> (2000) 82(2):270-277		
/WS/	BD	VAN DER FLIER, Silvia, et al. "Bcar 1/p130Cas Protein and Primary Breast Cancer: Prognosis and Response to Tamoxifen Treatment", <i>Journal of the National Cancer Institute</i> , (2000) Vol. 92(2):120-127		
/WS/	BE	LUO, L-Y, et al. "Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance", <i>British Journal of Cancer</i> (2002) 86:1790-1796		
/WS/	BF	ELLIS, Matthew J., et al. "Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect", <i>Journal of Steroid Biochemistry & Molecular Biology</i> (2003) 86:301-307		
/WS/	BG	HILSENBECK, Susan G., et al. "Statistical Analysis of Array Expression Data as Applied to the Problem of Tamoxifen Resistance", <i>Journal of the National Cancer Institute</i> (1999) 91(5):453-459		
/WS/	BH	VANT VEER, Laura, et al. "Gene expression profiling predicts clinical outcome of breast cancer", <i>Nature</i> (2002) 415:530-536		
/WS/	BI	MA, Xiao-Jun, et al. "A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen", <i>Cancer Cell</i> (2004) 5:607-615		
/WS/	BJ	BECKER, Michael, et al. "Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM", <i>Molecular Cancer Therapeutics</i> (2005) 4(1):151-168		
	BK	RAMASWAMY, Sridhar, et al., "A molecular signature of metastasis in primary solid tumors", <i>nature genetics</i> (2003) 33:49-54 NO COPY		
	BL			
	BM			

Examiner Signature	/Walter Schlakohl/	Date Considered	6 / 4 / 2007
--------------------	--------------------	-----------------	--------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449B/PTO				Complete if Known	
				<i>Application Number</i>	10/773,761
				<i>Filing Date</i>	February 6, 2004
				<i>First Named Inventor</i>	Erlander, Mark G.
				<i>Art Unit</i>	1634 1636
				<i>Examiner Name</i>	J.S. Gitton Schlapkohl
Sheet	1	of	1	<i>Attorney Docket Number</i>	022041-001420US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
/WS/	BC	BARDOU, V.J., et al. "Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases", <i>J. Clin Oncol</i> (2003) 21:1973-9		
	BD	HUANG, E. et al. "Gene expression predictors of breast cancer outcomes", <i>Lancet</i> (2003) 361:1590-6		
	BE	SØRLIE, T., et al. "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications", <i>Proc Natl Acad Sci USA</i> (2001) 98:10869-74		
	BF	SØRLIE, T., et al. "Repeated observation of breast tumor subtypes in independent gene expression data sets", <i>Proc Natl Acad Sci USA</i> (2003) 100:8418-23		
	BG	SOTIRIOU, C., et al. "Breast cancer classification and prognosis based on gene expression profiles from a population-based study", <i>Proc Natl Acad Sci USA</i> (2003) 100:10393-8		
	BH	van de VIJVER, M.J., et al. "A gene-expression signature as a predictor of survival in breast cancer", <i>N. Engl. J Med</i> (2002) 347:1999-2009		
	BI	FERNANDEZ M. D., et al. "Quantitative oestrogen and progesterone receptor values in primary breast cancer and predictability of response to endocrine therapy", <i>Clin Oncol</i> (1983) 9:245-50		
	BJ	FERNÖ, M., et al. "Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels", <i>Breast Cancer Res Treat</i> (2000) 59:69-76		
▼	BK	NARDELLI, G.B., et al. "Estrogen and progesterone receptors status in the prediction of response of breast cancer to endocrine therapy (preliminary report)", <i>Eur J Gynaecol Oncol</i> (1986) 7:151-8		
/WS/	BL	OSBORNE, C.K., et al. "The value of estrogen and progesterone receptors in the treatment of breast cancer", <i>Cancer</i> (1980) 46:2884-8		
	BM			

Examiner Signature	/Walter Schlapkohl/	Date Considered	6/4/2007
--------------------	---------------------	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO				Complete if Known	
				Application Number	10/773,761
				Filing Date	February 6, 2004
				First Named Inventor	Erlander, Mark G.
				Art Unit	1604 1636
				Examiner Name	J.S. Sillitoe Schlapkohl
Sheet	1	of	2	Attorney Docket Number	022041-001420US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/WS/	AA	US-2003/0219760 A1	11/27/03	Gordon et al.	
	AB	US-			
	AC	US-			
	AD	US-			
	AE	US-			
	AF	US-			
	AG	US-			
	AH	US-			
	AI	US-			
	AJ	US-			
	AK	US-			
	AL	US-			
	AM	US-			
	AN	US-			
	AO	US-			
	AP	US-			
	AQ	US-			
	AR	US-			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴				
	AS						<input type="checkbox"/>
	AT						<input type="checkbox"/>
	AU						<input type="checkbox"/>
	AV						<input type="checkbox"/>
	AW						<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Application Number</i>	10/773,761
				<i>Filing Date</i>	February 6, 2004
				<i>First Named Inventor</i>	Erlander, Mark G.
				<i>Art Unit</i>	1634 1636
				<i>Examiner Name</i>	J.S. Sittor Schlapkohl
Sheet	2	of	2	Attorney Docket Number	022041-001420US

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
/WS/	BA	HOWELL, Sacha J., et al. "The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer", <i>Best Practice & Research Clinical Endocrinology & Metabolism</i> (2004) 18(1):47-66			<input type="checkbox"/>
/WS/	BB	HALL, Julie M., et al. "The Multifaceted Mechanisms of Estradiol and Estrogen Receptor Signaling", <i>The Journal of Biological Chemistry</i> (2001) 276(40):36869-36872			<input type="checkbox"/>
/WS/	BC	LEVENSON, Anait S., et al. "Gene Expression Profiles with Activation of the Estrogen Receptor α-Selective Estrogen Receptor Modulator Complex in Breast Cancer Cells Expressing Wild-Type Estrogen Receptor", <i>Cancer Research</i> (2002) 62:4419-4426			<input type="checkbox"/>
/WS/	BD	JORDAN, V. Craig, et al. "Introducing a new section to <i>Breast Cancer Research: Endocrinology and hormone therapy</i> ", <i>Breast Cancer Research</i> (2003) 5:281-283			<input type="checkbox"/>
/WS/	BE	DAUVOIS, Sophie, et al. "Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover", <i>Proc. Natl. Acad. Sci.</i> (1992) 89:4037-4041			<input type="checkbox"/>
/WS/	BF	WILLSON, T.M., et al. "Dissection of the Molecular Mechanism of Action of GW5638, a Novel Estrogen Receptor Ligand, Provides Insights into the Role of Estrogen Receptor in Bone", <i>Endocrinology</i> (1997) 138(9):3901-3911			<input type="checkbox"/>
/WS/	BG	WIJAYARATNE, Ashini L., et al. "Comparative Analyses of Mechanistic Differences Among Antiestrogens", <i>Endocrinology</i> (1999) 140(12):5828-5840			<input type="checkbox"/>
/WS/	BH	DUTERTRE, Martin, et al "Molecular Mechanisms of Selective Estrogen Receptor Modulator (SERM) Action", <i>The Journal of Pharmacology and Experimental Therapeutics</i> (2000) 295(2):431-437			<input type="checkbox"/>
	BI				<input type="checkbox"/>
	BJ				<input type="checkbox"/>

Examiner Signature	/Walter Schlapkohl/	Date Considered	6 / 4 / 2007
--------------------	---------------------	-----------------	--------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.